Impact of Predicting Anti-angiogenic Response in mRCC Using Functional Imaging (REMISCAN)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00842790|
Recruitment Status : Completed
First Posted : February 12, 2009
Last Update Posted : October 6, 2015
The goal is to study the impact of functional MRI and CT evaluation of changes in tumor vessels induced by anti-angiogenic treatment in patients with metastatic RCC.
The hypothesis is that good responders and poor responders will have different responses induced by anti-angiogenic treatment, and that the detection of theses changes by functional imaging can improve the therapeutic management.
Functional CT and MRI will be performed in 200 patients before the beginning of antiangiogenic treatment, 7 days after and every 6 week until tumor progression (as defined by the RECIST criteria). Perfusion and diffusion parameters will be measured using a dedicated software.
|Condition or disease|
|Carcinoma, Renal Cell|
Show Detailed Description
|Study Type :||Observational|
|Actual Enrollment :||107 participants|
|Official Title:||Medical and Economical Impact of Predicting the Response to Anti-angiogenic Treatment in Metastatic Renal Cell Carcinoma Using Functional CT and MRI|
|Study Start Date :||September 2008|
|Actual Primary Completion Date :||July 2014|
|Actual Study Completion Date :||July 2014|
- RECIST criteria evolution [ Time Frame: at day 7 and after every 6 at 16 weeks during 2 years ]time-to-progression with anti-angiogenic traitment evaluated by RECIST criteria
- Validation of the technical and acquisition measurement models [ Time Frame: at day 7 and after every 6 at 16 weeks during 2 years ]Validation of the technical and acquisition measurement models of tumor perfusion MRI and CT, and diffusion MRI, study of reproducibility
- Assessment of potential drug costs [ Time Frame: at the end ]Assessment of potential drug costs avoided by use of innovative prognostic criteria for adapting treatment
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00842790
|service of oncology- HEGP|
|Paris, France, 75015|
|Principal Investigator:||Stephane OUDARD, PhD||Assistance Publique - Hôpitaux de Paris|
|Study Director:||Charles-André Cuenod, PhD||Assistance Publique - Hôpitaux de Paris|